SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-024866
Filing Date
2020-05-13
Accepted
2020-05-13 09:01:24
Documents
72
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-10q_20200331.htm 10-Q 2182961
2 EX-10.1 fulc-ex101_13.htm EX-10.1 80916
3 EX-31.1 fulc-ex311_7.htm EX-31.1 11514
4 EX-31.2 fulc-ex312_6.htm EX-31.2 12322
5 EX-32.1 fulc-ex321_8.htm EX-32.1 6273
6 EX-32.2 fulc-ex322_9.htm EX-32.2 6175
  Complete submission text file 0001564590-20-024866.txt   6781735

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT fulc-20200331.xml EX-101.INS 1248016
8 XBRL TAXONOMY EXTENSION SCHEMA fulc-20200331.xsd EX-101.SCH 51054
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fulc-20200331_cal.xml EX-101.CAL 47175
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fulc-20200331_def.xml EX-101.DEF 185225
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20200331_lab.xml EX-101.LAB 401449
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20200331_pre.xml EX-101.PRE 332694
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 20871256
SIC: 2834 Pharmaceutical Preparations